Skip to main content

Table 1 Baseline patient demographics

From: The impact of a heart failure management protocol based on a hospital-community pharmacist collaboration

 

Overall cohort (n = 68)

Intervention group (n = 28)

Control group (n = 40)

p

Age (years, mean ± SD)

80.8 ± 11.8

80.0 ± 8.9

81.3 ± 10.8

0.662

Male, n (%)

41 (60.3)

15 (53.6)

26 (65.0)

0.451

Living alone, n (%)

8 (11.8)

6 (21.4)

2 (5.0)

0.057

Medical history, n (%)

    

 Diabetes mellitus

20 (29.4)

8 (28.6)

12 (30.0)

1.000

 Previous HF admission

27 (39.7)

13 (46.4)

14 (35.0)

0.451

 Ischemic heart disease

29 (42.6)

13 (46.4)

16 (40.0)

0.627

 Artral fibrillation

50 (73.5)

19 (67.9)

31 (77.5)

0.375

 Previous CABG

4 (5.9)

3 (10.7)

1 (2.5)

0.298

 Previous PCI

21 (30.9)

10 (35.7)

11 (27.5)

0.595

Physical examination

    

 Systolic blood pressure (mmHg, mean ± SD)

111.6 ± 16.3

113.4 ± 17.4

110.3 ± 15.6

0.447

 Diastolic blood pressure (mmHg, mean ± SD)

65.2 ± 11.5

65.8 ± 11.0

64.8 ± 11.9

0.600

 Body mass index (kg/m2), n (%)

20.7 ± 3.9

21.0 ± 3.1

20.5 ± 4.4

0.252

 LVEF

50.5 ± 15.1

49.6 ± 13.6

51.2 ± 5.3

0.570

 LVEF < 50, n (%)

31 (45.6)

14 (50.0)

17 (42.5)

0.624

 Albumin (g/dL, mean ± SD)

3.2 ± 0.4

3.2 ± 0.4

3.2 ± 0.5

0.549

 Creatinine (mg/dL, mean ± SD )

1.29 ± 0.6

1.31 ± 0.6

1.27 ± 0.6

0.847

 Blood urea nitrogen (mg/dL, mean ± SD)

29.2 ± 14.4

28.5 ± 12.4

29.7 ± 15.8

0.945

 eGFR (mL/min/1.73m2, mean ± SD2)

45.3 ± 21.0

43.0 ± 18.7

47.0 ± 22.5

0.455

 Hemoglobin (g/dL, mean ± SD)

12.1 ± 2.1

12.2 ± 2.0

12.0 ± 2.2

0.566

 Creatinine clearance (mL/min, mean ± SD)

37.7 ± 22.9

36.9 ± 21.4

38.2 ± 24.2

0.921

 NT-proBNP (pg/mL), median (IQR)

2380 (1335–4549)

3033 (1622–6306)

1749 (1226–3736)

0.100

Medication, n (%)

    

 Aspirin

11 (16.2)

3 (10.7)

8 (20.0)

0.505

 OACs

40 (58.8)

16 (57.1)

24 (60.0)

1.000

 Beta-blocker

53 (77.9)

21 (75.0)

32 (80.0)

0.768

 ACEi/ARB/ARNI

44 (64.7)

20 (71.4)

24 (60)

0.441

 MRA

38 (55.9)

19 (67.9)

19 (47.5)

0.137

 SGLT2i

30 (44.1)

10 (35.7)

20 (50.0)

0.322

 Loop diuretics

58 (85.3)

23 (82.1)

35 (87.5)

0.730

  1. SD, standard deviation; HF, heart failure; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; IQR, interquartile range; LVEF, left ventricle ejection Fraction; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro brain natriuretic peptide; OACs, oral anticoagulants; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor neprilysn inhibitors; MRA, mineralocorticoid receptor antagonists; SGLT2i, sodium-glucose cotransport-2 inhibitor
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us